Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
University of California, Irvine
Summary
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Description
This is a single-arm, prospective pilot/feasibility study. Treatment will continue for the duration of the study (18 months) or intolerance to treatment. The primary endpoint will be feasibility of metformin therapy in patients with PMP secondary to AMNs.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria (complete details available in protocol): * Patients with clinical diagnosis of PMP secondary to presumed AMNs with recurrent/refractory disease s/p CRS/HIPEC, unresectable disease, or without planned CRS/HIPEC * Age ≥18 years * ECOG performance status ≤2 Key Exclusion Criteria (complete details available in protocol): * Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC * Patients currently taking metformin for another medical indication * Patients with a prior adverse event to administrat…
Interventions
- DrugMetformin
Given PO
Location
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, California